Marien Hospital Witten

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer8 trials
• Triple-negative breast cancer4 trials
• Gastric and oesophageal cancer3 trials
• Colorectal cancer2 trials
• Liver and biliary tract cancer2 trials
• Pancreatic cancer2 trials
• Cervical cancer1 trial
• Endometrial cancer1 trial

Phase

• Phase 310 trials
• Phase 23 trials
• Phase 2/32 trials

Status

• Recruiting11 trials
• Completed4 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest2 trials
• AstraZeneca1 trial
• Canadian Cancer Trials Group1 trial
• Dominik Paul Modest1 trial
• DualityBio Inc.1 trial
• and 12 more

Running trials

• Not yet recruiting

  NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  NCT07178730· Phase 3· Women's Cancer Study Group GmbH· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

  Contact: Monika Graeser (principal investigator)

• Recruiting

  A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)

  2024-511392-15-00· Phase 3· WSG Women's Cancer Study Group GmbH· Source

• Recruiting

  Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

  NCT06954480· Phase 2· Queen Mary University of London· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Dominik Paul Modest· Source

• Recruiting

  Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

  NCT06201234· Phase 2· GBG Forschungs GmbH· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Recruiting

  HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

  NCT04447352· Phase 3· Krankenhaus Nordwest· Source

• Active, not recruiting

  Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

  NCT03595592· Phase 3· Fondazione Michelangelo· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer6 recruiting
• Triple-negative breast cancer4 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting

Closed trials

• Recruiting

  Sacituzumab Govitecan in Metastatic Colorectal Cancer

  NCT06243393· Phase 2/3· University Hospital Heidelberg· Source

• Active, not recruiting

  A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

  NCT06018337· Phase 3· DualityBio Inc.· Source

• Terminated

  The PLATON Network

  NCT05489250· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

  NCT04484636· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Canadian Cancer Trials Group· Source